Creon (Atlantic Biologicals Corps)


Welcome to the PulseAid listing for the Creon drug offered from Atlantic Biologicals Corps. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Atlantic Biologicals Corps
NON-PROPRIETARY NAME: Pancrelipase
SUBSTANCE NAME: PANCRELIPASE LIPASE; PANCRELIPASE PROTEASE; PANCRELIPASE AMYLASE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS:
ROUTE: ORAL
DOSAGE FORM: CAPSULE, DELAYED RELEASE PELLETS
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2010-08-13
END MARKETING DATE: 0000-00-00


Creon HUMAN PRESCRIPTION DRUG Details:

Item DescriptionCreon from Atlantic Biologicals Corps
LABELER NAME: Atlantic Biologicals Corps
DEA SCHEDULE:
ACTIVE STRENGTH: 6000; 19000; 30000([USP’U]/1; [USP’U]/1; [USP’U]/1)
START MARKETING DATE: 2010-08-13
END MARKETING DATE: 0000-00-00
PRODUCT ID: 17856-1206_c409a22d-9e77-4cf5-b8db-3d2f0d544fa1
PRODUCT NDC: 17856-1206
APPLICATION NUMBER: NDA020725

Other PANCRELIPASE LIPASE; PANCRELIPASE PROTEASE; PANCRELIPASE AMYLASE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AbbVie Inc.Creon
Allergan, Inc.Zenpep
Aptalis Pharma US, IncULTRESA
Aptalis Pharma US, Inc.ZENPEP
Atlantic Biologicals CorpsCreon
Physicians Total Care, Inc.ZENPEP
X-GEN Pharmaceuticals, Inc.PANCRELIPASE